131i-tenatumomab
mAbexperimentalADC
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02602067)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- TenascinRadiodepletion
TNC radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 131i-tenatumomab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02602067 | Phase 1 | Nov 1, 2015 | Fondazione Giovanni Pascale, Leadiant Biosciences, Inc., Medpace, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fondazione Giovanni Pascale | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Leadiant Biosciences, Inc. | For profit | 1 | 1 | 1 | 2015 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1